Evaxion Biotech A/S(EVAX)Earnings, Financials & Key Ratios
EVAX•NASDAQ
$3.31
Price updated Jul 7, 2026
AboutEvaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.Show more
- Revenue$8M+125.1%
- EBITDA-$9M+39.0%
- Net Income-$8M+27.1%
- EPS (Diluted)-1.21+87.7%
- Gross Margin100%
- EBITDA Margin-114.49%+72.9%
- Operating Margin-122.66%+72.2%
- Net Margin-102.38%+67.6%
- ROE-100.18%
EVAX Price & Volume
Evaxion Biotech A/S (EVAX) stock price & volume — 10-year historical chart
Loading chart...
Volatile Milestone Revenue Masks Persistent Operational Deficits
Investment Thesis • Updated 2025Q4
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical milestone dependency
Key Thesis Takeaways
- Evaxion Biotech remains a high-risk, clinical-stage entity whose valuation is tethered to the success of its AI-driven PIONEER platform rather than consistent commercial performance.
- The company's reliance on lumpy milestone payments, evidenced by a 148.3% revenue surge in 2025Q3 followed by zero revenue in 2025Q4, creates significant uncertainty regarding long-term financial sustainability.
- Investors should monitor the firm's ability to extend its $23.2M cash runway, as the persistent accumulation of a $126.2M retained earnings deficit suggests a continued dependency on dilutive financing to fund ongoing R&D.
Verdict Logic
the company's reliance on intermittent milestone payments and a $126.2M retained earnings deficit suggests that the current $23.2M cash position may be insufficient to support long-term clinical development without further shareholder dilution.
EVAX Growth Metrics
Evaxion Biotech A/S (EVAX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM125.15%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM27.03%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM80.98%
Return on Capital
10 Years-315.78%
5 Years-133.44%
3 Years-151.11%
Last Year-57.23%
Peers Comparison
Key metrics vs top competitors for Evaxion Biotech A/S (EVAX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.31 | $20.91M | -2.74 | 125.12% | -102.38% | -100.18% | — | |
| $0.93 | $15.58M | 1.82 | -33.66% | 386.64% | 38.45% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $4.35 | $1.56B | -3.99 | 60.6% | -123.9% | -50.17% | — | |
| $136.36 | $169.3B | 20.11 | 2.39% | 30.99% | 42.33% | — |
Compare EVAX vs Peers
Evaxion Biotech A/S (EVAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when EVAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EVAX Frequently Asked Questions
Evaxion Biotech A/S (EVAX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Evaxion Biotech A/S's revenue?
Evaxion Biotech A/S (EVAX) reported $7.5M in revenue for fiscal year 2025.
How fast is Evaxion Biotech A/S growing?
Evaxion Biotech A/S (EVAX) grew revenue by 125.1% over the past year. This is strong growth.
Is EVAX profitable?
Evaxion Biotech A/S (EVAX) reported a net loss of $7.7M for fiscal year 2025.
Dividend & Returns
What is EVAX's return on equity?
Evaxion Biotech A/S (EVAX) has a return on equity (ROE) of -100.2%. Negative ROE indicates the company is unprofitable.
What is Evaxion Biotech A/S's free cash flow?
Evaxion Biotech A/S (EVAX) had negative free cash flow of $6.7M in fiscal year 2025, likely due to heavy capital investments.